NGR-hTNF

DRUG15 trials

Sponsors

AGC Biologics S.p.A., Andres J. M. Ferreri

Conditions

Advanced Malignant Pleural MesotheliomaAdvanced Solid TumorsCancerColon CancerColorectal Cancer (CRC)Hepatocellular CarcinomaLymphoma, Large B-Cell, DiffuseMalignant Pleural Mesothelioma

Phase 1

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

CompletedNCT00305084

AGC Biologics S.p.A.Cancer

Start: 2006-02-28End: 2007-05-08Updated: 2019-10-04

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

CompletedNCT00419328

AGC Biologics S.p.A.Advanced Solid Tumors

Start: 2005-03-31End: 2007-09-30Updated: 2022-07-21

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

CompletedNCT00483093

AGC Biologics S.p.A.Solid Tumors

Start: 2007-07-31End: 2013-04-30Updated: 2014-05-30

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

CompletedNCT00878111

AGC Biologics S.p.A.Solid Tumors

Start: 2009-04-30End: 2017-02-28Updated: 2018-08-29

Phase 2

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

CompletedNCT00483080

AGC Biologics S.p.A.Colorectal Cancer (CRC)

Start: 2006-12-31End: 2013-04-30Updated: 2019-01-16

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

CompletedNCT00483509

AGC Biologics S.p.A.Small Cell Lung Cancer

Start: 2007-02-14End: 2011-05-17Updated: 2019-10-04

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

CompletedNCT00484211

AGC Biologics S.p.A.Hepatocellular Carcinoma

Start: 2006-12-31End: 2013-04-30Updated: 2014-05-30

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

CompletedNCT00484276

AGC Biologics S.p.A.Malignant Pleural Mesothelioma

Start: 2007-05-31End: 2013-03-31Updated: 2019-01-16

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

CompletedNCT00484432

AGC Biologics S.p.A.Ovarian Cancer Metastatic Recurrent

Start: 2008-11-30End: 2016-06-30Updated: 2018-09-27

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

CompletedNCT00675012

AGC Biologics S.p.A.Colon Cancer

Start: 2007-12-31End: 2013-05-31Updated: 2014-05-30

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

CompletedNCT00994097

AGC Biologics S.p.A.Non-small Cell Lung Cancer

Start: 2009-07-31End: 2017-03-31Updated: 2018-09-27

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

CompletedNCT01358084

AGC Biologics S.p.A.Advanced Malignant Pleural Mesothelioma

Start: 2011-03-31End: 2018-12-05Updated: 2019-01-15

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

CompletedNCT01358071

AGC Biologics S.p.A.Ovarian Cancer

Start: 2011-06-30End: 2016-12-31Updated: 2018-09-27

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

CompletedNCT03536039

Andres J. M. FerreriLymphoma, Large B-Cell, Diffuse

Start: 2016-01-27End: 2020-01-27Updated: 2022-08-03

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

CompletedNCT03804866

AGC Biologics S.p.A.Ovarian Cancer

Start: 2013-03-31End: 2016-12-31Updated: 2019-01-15

Related Papers

R‐CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL

Hematological Oncology2019-06-011 citations

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Blood2019-05-2250 citations

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Blood2018-11-29

Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC).

Journal of Clinical Oncology2014-05-202 citations

Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy.

Journal of Clinical Oncology2014-05-20

Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM).

Journal of Clinical Oncology2014-05-20